Orteronel Leaves Hole In Millennium/Takeda Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.
You may also be interested in...
Takeda’s Tachi Yamada Discusses The Late-Stage Pipeline: An Interview At PSA 2013
In an interview with “The Pink Sheet” at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business and of the key late-stage assets that will carry the company into the next decade.
Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker